

# Implementing cloud computing in drug discovery and telemedicine for quantitative structure-activity relationship analysis

Palayanoor Seethapathy Ramaprabha<sup>1</sup>, Bellam Ravindra Babu<sup>2</sup>, Nallathampi Rajamani Rejin Paul<sup>3</sup>,  
Varadan Sharmila<sup>4</sup>, Venkatachalam Ramesh Babu<sup>5</sup>, Raman Ramya<sup>6</sup>, Subbiah Murugan<sup>7</sup>

<sup>1</sup>Department of Electrical and Electronics Engineering, Panimalar Engineering College, Chennai, India

<sup>2</sup>Department of Computer Science and Engineering Department, Adama Science and Technology University, Adama, Ethiopia

<sup>3</sup>Department of Computer Science and Engineering, R.M.K. College of Engineering and Technology, Chennai, India

<sup>4</sup>Department of Computer Science and Engineering, R.M.D. Engineering College, Chennai, India

<sup>5</sup>Department of Computer Science and Engineering, Dr.MGR Educational and Research Institute, Chennai, India

<sup>6</sup>Department of Electronics and Communication Engineering, Chennai Institute of Technology, Chennai, India

<sup>7</sup>Department of Biomedical Engineering, Saveetha School of Engineering, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai, India

## Article Info

### Article history:

Received Dec 14, 2023

Revised Sep 7, 2024

Accepted Oct 1, 2024

### Keywords:

Chemoinformatics

Cloud computing

Drug discovery

Quantitative structure-activity

Relationship analysis

## ABSTRACT

This work aims to use cutting-edge machine learning methods to improve quantitative structure-activity relationship (QSAR) analysis, which is used in drug development and telemedicine. The major goal is to examine the performance of several predictive modeling approaches, including random forest, deep learning-based QSAR models, and support vector machines (SVM). It investigates the potential of feature selection techniques developed in chemoinformatics for enhancing model accuracy. The innovative aspect is using cloud computing resources to strengthen computational skills, allowing for managing massive amounts of chemical information. This strategy produces accurate and generalizable QSAR models. By using the cloud's scalability and constant availability, remote healthcare apps have a workable answer. The goal is to show how these methods may improve telemedicine and the drug development process. Utilizing cloud computing equips researchers with a flexible set of tools for precise and timely QSAR analysis, speeding up the discovery of bioactive chemicals for therapeutic use. This new method fits well with the dynamic nature of pharmaceutical study and has the potential to transform the way drugs are developed and delivered to patients via telemedicine.

This is an open access article under the [CC BY-SA](https://creativecommons.org/licenses/by-sa/4.0/) license.



## Corresponding Author:

Palayanoor Seethapathy Ramaprabha

Department of Electrical and Electronics Engineering, Panimalar Engineering College

Bangalore Trunk Road, Varadharajapuram, Poonamallee, Chennai, Tamil Nadu 600123, India

Email: ramaprabatamilselvan@gmail.com

## 1. INTRODUCTION

Cloud computing has evolved as a game-changing technology that provides unmatched computational power and storage capacity to various industries, including telemedicine and drug development. Exploiting cloud computing resources has substantially improved the efficacy and accuracy of predictive modeling in the context of quantitative structure-activity relationship analysis, which plays a vital role in identifying new drugs [1]. This is because quantitative structure-activity relationship (QSAR) analysis is one of the most important aspects of drug discovery. Researchers can speed up the analysis of massive

datasets, which enables the discovery of prospective drug candidates with improved accuracy. This is made possible by using the scalability and flexibility of cloud platforms. Cloud computing has been adopted by the booming field of telemedicine, which seeks to bridge the gap between healthcare practitioners and patients by using digital platforms. This allows telemedicine to offer distant healthcare services smoothly [2]. The drug development method has been completely transformed due to the incorporation of cloud computing resources into QSAR analysis. Even though they have their uses, traditional QSAR approaches often need help to meet the computational demands imposed by intricate biological interactions and huge chemical libraries [3]. Cloud-based infrastructures make it easier for researchers to work together on projects. This makes it possible for researchers in different parts of the world to work together in real-time, which in turn encourages a lively interchange of ideas and approaches [4].

Cloud computing has been a driving element behind the rise of telemedicine as a potentially disruptive force in the healthcare business. These platforms may provide various telemedicine services to patients, including remote consultations and real-time monitoring of vital signs [5]. Cloud-based telemedicine solutions increase the availability of healthcare services and facilitate the smooth flow of medical information among healthcare professionals. This aids healthcare providers in diagnosing diseases, predicting trends, and personalizing treatment plans, ultimately revolutionizing how healthcare is delivered and experienced [6]. Although using cloud computing in QSAR analysis and telemedicine has led to significant leaps forward, several obstacles still need to be overcome. Guaranteeing the interoperability of various cloud-based systems and apps is essential for enabling smooth communication and data interchange across the healthcare ecosystem [7]. For the foreseeable future, ongoing research endeavors are concentrating on improving the accuracy of predictive models, optimizing cloud computing algorithms for QSAR analysis, and exploring innovative ways to leverage cloud-based technologies for telemedicine applications. As the integration of cloud computing continues to evolve, its synergy with QSAR analysis and telemedicine holds the promise of shaping a future where personalized medicine and remote healthcare services are both a possibility and a global reality [8]. Cloud-based data analytics have emerged as a cornerstone in drug development and telemedicine. These analytics provide insights into intricate biological interactions and patient healthcare data that are unmatched by any other method [9]. Data analytics play an essential part in understanding patient data in telemedicine. This enables healthcare practitioners to recognize patterns, anticipate illness outbreaks, and develop the most effective treatment regimens [10]. Cloud computing's scalability and cost-effectiveness are key advantages in drug development and telemedicine [11]. Pay-as-you-go methods may be used by researchers and healthcare organizations, allowing them to pay only for the resources that they use. This strategy, which is both cost-effective and democratizes access to sophisticated computing capabilities, levels the playing field for researchers and healthcare institutions, regardless of how large they are or how much money they have [12].

Cloud service providers must comply with high regulatory requirements such as the health insurance portability and accountability act in the United States and the general data protection regulation in Europe. These laws and regulations were enacted to protect the privacy and security of patient health information. By ensuring that patient data is managed in a manner that is both ethical and lawful, compliance with these rules helps to create confidence between healthcare practitioners, patients, and providers of cloud services [13]. The combination of artificial intelligence (AI) and cloud computing is on the cusp of radically altering the trajectory of both drug research and telemedicine in the future. Patients may get rapid medical advice, book appointments, and receive prescription reminders using AI-driven chatbots and virtual assistants in telemedicine. These technologies are powered by cloud-based machine-learning algorithms [14]. Predictive analytics that AI powers give healthcare practitioners insights into their patients' behavior patterns, allowing them to react proactively, preventing illnesses and promoting healthy lives. As AI continues to evolve and integrate seamlessly with cloud computing, this promise holds the promise of creating a healthcare landscape that is not only highly personalized but also highly accessible [15]. The extensive use of cloud computing in drug development and telemedicine raises several important ethical and societal questions that must be thoroughly investigated [16].

Overcoming challenges in integrating cloud computing for enhanced quantitative structure-activity relationship analysis in drug discovery and telemedicine: Data analytics and computing are transforming telemedicine and drug research. QSAR analysis is essential for understanding this industry's compound chemical structures and biological activities. Dataset complexity and processing make traditional QSAR analysis harder. Creative solutions are required to hasten medication development and enhance telemedicine as data volume and complexity rise. Cloud computing may improve QSAR analysis. The cloud lets researchers manage enormous amounts of data and do sophisticated real-time calculations, speeding up medication candidate selection and improving telemedicine protocol. Cloud computing for QSAR analysis is difficult. The lack of standardized cloud QSAR analysis tools are a problem. Frameworks with cloud infrastructures produce analytical inefficiencies and consistency. Security and privacy of sensitive medical data during cloud-based analysis are key considerations. Unauthorized access, data breaches, and regulatory

compliance must be addressed to establish credibility and acceptability for pharmaceutical and telemedicine cloud-based QSAR analysis. QSAR analysis demands strong computer clusters and rapid algorithms for complicated calculations. Researchers must balance analytical precision and cost-effective cloud resource utilization. Researchers and healthcare professionals need to learn cloud-based QSAR analysis's merits and downsides, which inhibits its implementation. Here, cloud computing for QSAR analysis in drug development and telemedicine is discussed. The project intends to smoothly incorporate cloud-based QSAR analysis into pharmaceutical and telemedicine enterprises by addressing methodological issues, enhancing resource allocation, ensuring robust security, and promoting awareness. This might change drug discovery, speed up medication development, and improve telemedicine, increasing worldwide patient outcomes.

Using cloud computing for QSAR in drug discovery and telemedicine: Drug development and telemedicine use QSAR analysis to understand complicated chemical-biological connections. The industry may change with cloud computing. Integrating cloud computing for QSAR analysis is tough, but this Research offers novel concepts and practical methods that might transform drug development and telemedicine. Standardized cloud-based QSAR analysis methodologies are an important research contribution. By designing cloud-compatible processes, the work improves analytical consistency, efficiency, and reliability across datasets. These strategies let academics and practitioners use cloud computing to speed up drug research and improve telemedicine. This enhances the privacy and security of cloud-based QSAR analysis. Robust encryption, access controls, and regulatory compliance protect medical data. The study addresses these concerns to enhance stakeholder confidence in cloud-based QSAR analysis's integrity and confidentiality, allowing pharmaceutical and telemedicine uptake. This study relies on creative resource optimization. Complex QSAR calculations and cost-effective cloud resource consumption is tough to reconcile. By optimizing algorithms and computing resources, Research yields high-quality results at minimal cost. This effective resource usage makes cloud-based QSAR analysis sustainable, scalable, and affordable for academics and enterprises of all sizes. Cloud-based QSAR analysis is advocated.

## 2. LITERATURE REVIEW

Underserved groups may not have access to the essential technology and infrastructure, which limits their ability to participate in cloud-based healthcare solutions. This problem is caused by the digital divide, which offers a societal barrier. To bridge this gap, deliberate efforts must be made to enable equitable access to cloud-based telemedicine services [17]. The development of telemedicine and drug discovery will likely be significantly impacted by collaborative research projects made possible by cloud computing systems. This spirit of cooperation helps to create a thriving research community in which the exchange of information helps to speed up the discovery of new scientific findings and improves the creation of breakthrough treatments [18]. Open-access databases and cloud-based platforms further democratize knowledge by giving scholars access to important resources independent of their physical location or the institutions they are affiliated with [19]. Data centers, essential to the operation of cloud computing, are responsible for a large amount of energy consumption [20].

To lessen their impact on the environment, suppliers of cloud services are making financial investments in energy-saving technology and investigating novel methods such as liquid cooling. The healthcare business may leverage the potential of cloud computing responsibly by adopting methods that benefit the environment. This will link the aims of technology growth with environmental conservation [21]. A new age of innovation and accessibility has begun with the use of cloud computing in quantitative structure-activity connection studies in drug research and telemedicine. This promises a future in which personalized medicine and remote healthcare are not just possibilities but fundamental rights for all [22], [23]. The use of cloud-based technologies in drug research and telemedicine presents not just complex legal difficulties but also the need for comprehensive regulatory frameworks. Creating a safe environment for cloud-based healthcare efforts and instilling trust among patients, healthcare providers, and researchers alike may be accomplished via the active pursuit of international cooperation in establishing uniform laws [24]–[26]. Computing in the cloud not only revolutionizes the technological elements of healthcare but also alters the experience of being a patient. Patients are given more agencies when cloud-based telemedicine technologies provide them easy access to medical consultations, individualized health data, and interactive tools for self-monitoring. Patients can now engage in real-time consultations with medical specialists, seek second views, and actively participate in the treatment plans being developed for them, thanks to secure cloud connections [27], [28]. These platforms allow patients and healthcare practitioners to remain in constant contact with one another, resulting in increased adherence to treatment regimens and improved management of chronic illnesses. Not only can cloud-based telemedicine cover geographical boundaries, but it also deepens the patient-provider connection, which helps create a

collaborative approach to the delivery of healthcare [29]. The detailed study follows the proposed system, results and discussion, conclusion.

### 3. PROPOSED SYSTEM

#### 3.1. Cloud computing revolutionizing QSAR analysis in drug discovery and telemedicine

Cloud computing is leading drug discovery and telemedicine transformation, changing QSAR analysis. The seamless integration of new computational methods, which provide many benefits, applications, and advantages, highlights its importance in various sectors. Figure 1 depicts coronavirus disease 2019 (COVID-19) related AI-based medical picture recognition and analysis. Here, input like X-ray and computed tomography (CT) scan data sets are classified by applying a deep learning algorithm through image processing and augmentation.




Figure 1. COVID-19-related deep learning medical image recognition and analysis schematic

#### 3.2. Drug discovery and telemedicine quantitative structure-activity relationship analysis using cloud computing

Cloud computing is disrupting medication research and telemedicine. It has transformed QSAR analysis in several disciplines, changing how academics and healthcare professionals approach complicated problems [30]. This transition revolves around cloud computing. It has revolutionized drug development by giving researchers access to massive computer resources and cutting-edge methods. Figure 2 shows some of the ways digital technologies are employed in medication development. This figure consists of two divisions: discovery and development.




Figure 2. An overview of applications of digital health technologies in drug discovery and development

#### 3.3. Drug discovery and telemedicine: cloud computing for QSAR analysis with random forest

In QSAR analysis, random forest (RF) algorithm and cloud computing have revolutionized drug discovery and telemedicine. RF algorithm and cloud-based platforms have revolutionized techniques in these

crucial sectors by improving efficiency, accuracy, and creativity. Cloud computing settings are ideal for RF algorithms, which can manage complicated information and develop reliable prediction models.

$$F(x) = \sum_{i=1}^N w_i \bullet I(x \in R_i) \quad (1)$$

Equation (1) presents the RF for QSAR analysis  $F(x)$ , which denotes the prediction for a given input  $x$ ,  $N$  is the number of decision trees in the forest,  $R_i$  represents the regions defined by the trees,  $w_i$  are the weights assigned to each region, and  $I(x \in R_i)$  is the indicator function determining if  $x$  falls within  $R_i$  when harnessed via cloud computing, this algorithm accelerates QSAR studies, enabling efficient drug discovery and telemedicine advancements through precise activity predictions based on molecular structures. QSAR analysis in drug discovery and telemedicine is revolutionized by cloud computing, as shown in Table 1. RF is stable and accurate, deep learning catches subtle patterns, support vector machines (SVM) handle high-dimensional data well, and chemoinformatics-based feature selection improves interpretability.

Table 1. Cloud-powered advances in QSAR analysis: revolutionizing drug discovery and telemedicine

Role	Benefit	Function	Application	Advantages
RF for QSAR analysis	More accurate predictions	Decision tree ensembles increase model accuracy.	Pharmaceutical discovery, toxicity forecast	Robust, complicated data, little overfitting
Deep learning-based QSAR model	Complex pattern recognition deep learning algorithms	Neural networks learn complex data patterns	Designing drugs, virtual screening, predicting compound properties	Learns from big datasets, accurately captures nonlinear connections
SVM for QSAR analysis	High-dimensionally effective	Mapping high-dimensional data points finds optimum hyperplane.	Predicting bioactivity and drug-target interactions	Good generalization, high-dimensional data, no overfitting
Chemoinformatics-based feature selection	Finding important molecular characteristics	Selects important chemical data characteristics	Choose features, identify molecular descriptors	Model interpretability, dimensionality reduction, and accuracy improved

These methods speed drug discovery and enable bioactivity predictions and molecular design using cloud platforms. Cloud-based solutions provide seamless collaboration, scalability, and resource optimization, making them essential for pharmaceutical Research and telemedicine. In vitro and silico models enable therapeutic effectiveness and toxicity testing without animal studies. In vitro models provide for novel in vivo modeling. Figure 3 explains drug safety and effectiveness test.

The figure summarizes current nonanimal model options for supporting animal awareness requirements, including replacing, lowering, and refining. It covers approaches for replacing animals in drug research to examine effects and reactions and uncover genetic pathways involved in drug development. Chemical absorption, distribution, metabolism, excretion, and toxicity (ADMET), enzyme assay, spheroid culture systems, QSAR models, organoid models, and spheroid culture systems improve drug safety and efficacy.




Figure 3. Drug safety and effectiveness test identification, protein, bioinformatics, and molecular dynamics simulations schematic

## 4. RESULTS AND DISCUSSION

### 4.1. A cloud-based deep learning-based QSAR model for drug discovery and telemedicine

Cloud computing and deep learning-based QSAR models have revolutionized drug discovery and telemedicine. This synergy uses artificial neural networks and cloud platforms to redefine QSAR analysis. This technique is revolutionizing pharmaceutical Research and telemedicine patient care by studying molecular interactions and using cloud-based computing tools [31].

$$y = f(X; \theta) \quad (2)$$

Equation (2) shows the deep learning-based QSAR model  $y$ , which represents a drug's predicted quantitative activity  $X$ , denotes the input features representing the drug's molecular structure, and  $\theta$  represents deep learning model parameters. Cloud computing powers the model, which processes huge molecular data remotely for reliable QSAR research. This technique improves prediction accuracy for drug discovery and telemedicine, speeds up chemical identification, allows individualized patient treatments, and transforms healthcare.

### 4.2. Using cloud computing for QSAR analysis in drug discovery and telemedicine using SVMs

SVM and cloud computing are transforming QSAR analysis. The strength of machine learning algorithms and cloud computing is transforming medication research and telemedicine. SVM and cloud computing are helping researchers investigate molecular structures, expedite medication discovery, and enhance telemedicine patient care. This unique approach uses SVM algorithms to find and predict complex data patterns. These algorithms examine chemical compounds and predict biological activity to assist medication developers in uncovering possibilities. SVM models deliver accurate telemedicine diagnosis and personalized treatment. High-dimensional SVM data processing enhances prediction accuracy, allowing targeted drug discovery and telemedicine therapy. Table 2 explains cloud-powered enhancements in QSAR.

Figure 4 shows drug discovery and telemedicine QSAR use per year. Columns show random forest, deep learning-based QSAR model, SVM, and chemoinformatics-based feature selection. Data shows the use of these techniques from 2018 to 2020. Random forest and chemoinformatics are widely used, suggesting their popularity.

Table 2. Cloud-powered enhancements in QSAR analysis

Aspect	Random forest for QSAR	Deep learning-based QSAR	SVM based QSAR	Chemoinformatics-based feature selection
Prediction accuracy	High	Very High	High	Moderate
Handling complex data	Yes	Yes	Yes	Yes
Interpretability	Moderate	Low	Low	High
Computational efficiency	Fast	Moderate	Moderate	Fast
Feature selection capability	No	No	No	Yes




Figure 4. Comparative analysis of QSAR techniques in drug discovery and telemedicine

### 4.3. Quantitative structure-activity relationship analysis in drug discovery and telemedicine using cloud-based chemoinformatics-based feature selection

The fusion of chemoinformatics-based feature selection techniques with cloud computing solutions has redefined the landscape of QSAR analysis, revolutionizing drug discovery and telemedicine practices. By harnessing the power of advanced chemoinformatics algorithms and the computational scalability of cloud platforms, researchers and healthcare professionals are unraveling the complexities of molecular interactions, paving the way for groundbreaking advancements in pharmaceutical research and personalized patient care. Chemoinformatics-based feature selection serves as the linchpin in this innovative approach. Researchers can use computational algorithms to identify essential molecular descriptors and structural features crucial for predicting biological activities. In drug discovery, this method streamlines the selection of potential drug candidates, allowing researchers to focus on compounds with the highest likelihood of success. RF, deep learning-based QSAR model, SVM, and chemoinformatics-based feature selection are compared in Figure 5. Each approach is tested for accuracy, sensitivity, and specificity. RF is most accurate (92%), then chemoinformatics feature selection (90%). SVM (88%) and deep learning-based QSAR (89%) are much less accurate. Methods have similar sensitivity and specificity.




Figure 5. Comparative analysis of QSAR techniques

## 5. CONCLUSION

This exemplifies how cutting-edge machine learning methods like RF, deep learning-based QSAR models, and support vector machines may revolutionize QSAR analysis. With the addition of cloud computing resources, computational power is further amplified, opening the door to managing large chemical datasets and improving the efficiency of models. This novel method not only has the potential to hasten the drug development process, but it also shows promise for telemedicine applications, providing a workable answer to the problem of healthcare delivery from a distance. To handle increasingly bigger and more complicated information, future research efforts should refine the integration of cloud computing resources and optimize computational operations. Research into alternative machine learning algorithms and unique feature selection approaches in chemoinformatics might lead to even better prediction model accuracy and generalizability. In addition, work must be done to improve the interpretability of models to shed light on the underlying chemical interactions. This framework needs extensive validation and testing to confirm its effectiveness and dependability before being used in real-world clinical situations. Computational chemists, pharmaceutical researchers, and healthcare providers must work together to ensure that these advances help patients. This has far-reaching consequences for improving healthcare outcomes since it lays the path for a new way of thinking about drug research and telemedicine. In the future, we provide security to data through a cloud system.

## REFERENCES





- [1] N. Kasoju *et al.*, "Digital health: trends, opportunities and challenges in medical devices, pharma and bio-technology," *CSI Transactions on ICT*, vol. 11, no. 1, pp. 11–30, 2023, doi: 10.1007/s40012-023-00380-3.
- [2] S. Sugandha, R. R. Choubey, R. K. Gupta, and S. B. Gupta, "Role of digital transformation and technology adoption in the efficiency of the pharmaceutical industry," *European Chemical Bulletin*, vol. 12, pp. 6862–6874, 2023.
- [3] S. P. S. Rao, U. H. Manjunatha, S. Mikolajczak, P. G. Ashigbie, and T. T. Diagana, "Drug discovery for parasitic diseases: powered by technology, enabled by pharmacology, informed by clinical science," *Trends in Parasitology*, vol. 39, no. 4, pp. 260–271, 2023, doi: 10.1016/j.pt.2023.01.010.
- [4] X. Xu *et al.*, "Mechanistic studies on aluminum-catalyzed ring-opening alternating copolymerization of maleic anhydride with epoxides: ligand effects and quantitative structure-activity relationship model," *Molecules*, vol. 28, no. 21, 2023, doi: 10.3390/molecules28217279.
- [5] H. J. Huang *et al.*, "Currently used methods to evaluate the efficacy of therapeutic drugs and kidney safety," *Biomolecules*, vol. 13, no. 11, 2023, doi: 10.3390/biom13111581.
- [6] S. Thakkar *et al.*, "Artificial intelligence and real-world data for drug and food safety – a regulatory science perspective," *Regulatory Toxicology and Pharmacology*, vol. 140, May 2023, doi: 10.1016/j.yrtph.2023.105388.
- [7] Q. Rafique *et al.*, "Reviewing methods of deep learning for diagnosing COVID-19, its variants and synergistic medicine combinations," *Computers in Biology and Medicine*, vol. 163, 2023, doi: 10.1016/j.combiomed.2023.107191.
- [8] S. Ma *et al.*, "Machine learning in TCM with natural products and molecules: current status and future perspectives," *Chinese Medicine (United Kingdom)*, vol. 18, no. 1, 2023, doi: 10.1186/s13020-023-00741-9.
- [9] K. G. Lockwood, V. Pitter, P. R. Kulkarni, S. A. Graham, L. A. Auster-Gussman, and O. L. H. Branch, "Predictors of program interest in a digital health pilot study for heart health," *PLOS Digital Health*, vol. 2, no. 7, 2023, doi: 10.1371/journal.pdig.0000303.
- [10] A. K. Bashir *et al.*, "A survey on federated learning for the healthcare metaverse: concepts, applications, challenges, and future directions," *arXiv:2304.00524*, pp. 1–15, 2023.
- [11] G. Thahniyath *et al.*, "Cloud based prediction of epileptic seizures using real-time electroencephalograms analysis," *International Journal of Electrical and Computer Engineering (IJECE)*, vol. 14, no. 5, pp. 6047–6056, Oct. 2024, doi: 10.11591/ijece.v14i5.pp6047-6056.
- [12] Y. Liu *et al.*, "Interpretable chirality-aware graph neural network for quantitative structure activity relationship modeling in drug discovery," *Proceedings of the 37th AAAI Conference on Artificial Intelligence, AAAI 2023*, vol. 37, pp. 14356–14364, 2023, doi: 10.1609/aaai.v37i12.26679.
- [13] Y. Matsuzaka and Y. Uesawa, "Ensemble learning, deep learning-based and molecular descriptor-based quantitative structure-activity relationships," *Molecules*, vol. 28, no. 5, 2023, doi: 10.3390/molecules28052410.
- [14] X. Huo, J. Xu, M. Xu, and H. Chen, "An improved 3D quantitative structure-activity relationships (QSAR) of molecules with CNN-based partial least squares model," *Artificial Intelligence in the Life Sciences*, vol. 3, 2023, doi: 10.1016/j.ails.2023.100065.
- [15] S. J. Belfield, M. T. D. Cronin, S. J. Enoch, and J. W. Firman, "Guidance for good practice in the application of machine learning in development of toxicological quantitative structure-activity relationships (QSARs)," *PLoS ONE*, vol. 18, no. 5 May, 2023, doi: 10.1371/journal.pone.0282924.
- [16] S. H. Park, H. G. Lee, X. Liu, S. K. Lee, and Y. T. Chang, "Quantitative structure-activity relationship of fluorescent probes and their intracellular localizations," *Chemosensors*, vol. 11, no. 5, 2023, doi: 10.3390/chemosensors11050310.
- [17] P. Iswanto, I. M. Firdaus, A. F. Dafaulhaq, A. G. Ramadhani, M. P. Saputri, and H. Ekowati, "Quantitative structure-activity relationship of 3-thiocyanate-1H-indoles derived compounds as antileukemia by AM1, PM3, and RM1 methods," *Jurnal Kimia Sains dan Aplikasi*, vol. 26, no. 3, pp. 109–117, 2023, doi: 10.14710/jksa.26.3.109-117.
- [18] T. R. Noviandy *et al.*, "Ensemble machine learning approach for quantitative structure activity relationship based drug discovery: a review," *Infolitika Journal of Data Science*, vol. 1, no. 1, pp. 32–41, 2023, doi: 10.60084/ijds.v1i1.91.
- [19] D. S. Megawati, J. Ekowati, and S. Siswandono, "Quantitative structure-activity relationship (QSAR) of N-benzoyl-N'-naphthylthiourea derivative compounds by in silico as anticancer through inhibition of VEGFR2 receptors," in *The International Conference on Green Technology and Energy Engineering*, 2023, pp. 137–148, doi: 10.2991/978-94-6463-148-7\_15.
- [20] R. T. Pusparini, A. A. Krisnadi, and Firdayani, "Math: a deep learning approach in QSAR for estrogen receptor alpha inhibitors," *Molecules*, vol. 28, no. 15, 2023, doi: 10.3390/molecules28155843.
- [21] R. Hadanu, S. Abd Samad, and M. Fath Azzajad, "Quantitative relationships analysis of structure and activity of asam-5-aryledene-N,N'-dimethylbarbituric derivatives as an uric acid drug," *SCIREA Journal of Medicine*, vol. 7, no. 2, pp. 1–16, 2023, doi: 10.54647/pm310205.
- [22] S. S. Duay, R. C. Y. Yap, A. L. Gaitano, J. A. A. Santos, and S. J. Y. Macalino, "Roles of virtual screening and molecular dynamics simulations in discovering and understanding antimalarial drugs," *International Journal of Molecular Sciences*, vol. 24, no. 11, 2023, doi: 10.3390/ijms24119289.
- [23] C. Lestari, E. Darwin, D. P. Putra, N. Suharti, and B. A. Gani, "The role of plant extracts in the repair of rattus norvegicus mandibular alveolar bone in a periodontitis model," *Rasayan Journal of Chemistry*, vol. 16, no. 3, pp. 1342–1350, 2023, doi: 10.31788/RJC.2023.1638159.
- [24] T. R. Noviandy, A. Maulana, T. Bin Emran, G. M. Idroes, and R. Idroes, "QSAR classification of beta-secretase 1 inhibitor activity in alzheimer's disease using ensemble machine learning algorithms," *Hecca Journal of Applied Sciences*, vol. 1, no. 1, pp. 1–7, 2023, doi: 10.60084/hjas.v1i1.12.
- [25] C. Dhande, D. Mistry, A. Karthic, R. Singh, and S. Barage, "Computational approaches to identify novel inhibitors for the drug-resistant Mycobacterium tuberculosis DprE1 enzyme," *Indonesian Journal of Biotechnology*, vol. 28, no. 3, pp. 180–190, 2023, doi: 10.22146/ijbiotech.80145.
- [26] A. P. Toropova, A. A. Toropov, A. Roncaglioni, and E. Benfenati, "Binding organophosphate pesticides to acetylcholinesterase: risk assessment using the Monte Carlo method," *Toxicological and Environmental Chemistry*, vol. 105, no. 1–7, pp. 19–27, 2023, doi: 10.1080/02772248.2023.2181348.
- [27] T. R. Saravanan, A. R. Rathinam, J. Lenin, A. Komathi, B. Bharathi, and S. Murugan, "Revolutionizing cloud computing: evaluating the influence of blockchain and consensus algorithms," in *2023 3<sup>rd</sup> International Conference on Smart Generation Computing, Communication and Networking, Smart Gencon*, 2023, doi: 10.1109/SMARTGENCON60755.2023.10442008.
- [28] M. J. Kumar, S. Mishra, E. G. Reddy, M. Rajmohan, S. Murugan, and N. A. Vignesh, "Bayesian decision model based reliable route formation in internet of things," *Indonesian Journal of Electrical Engineering and Computer Science (IJECS)*, vol. 34, no. 3, pp. 1665–1673, 2024, doi: 10.11591/ijeecs.v34.i3.pp1665-1673.







- [29] A. R. Rathinam, B. S. Vathani, A. Komathi, J. Lenin, B. Bharathi, and S. M. Urugan, "Advances and predictions in predictive auto-scaling and maintenance algorithms for cloud computing," in *2<sup>nd</sup> International Conference on Automation, Computing and Renewable Systems, ICACRS 2023 - Proceedings*, 2023, pp. 395–400, doi: 10.1109/ICACRS58579.2023.10404186.
- [30] M. D. A. Hasan, K. Balasubadra, G. Vadivel, N. Arunfred, M. V. Ishwarya, and S. Murugan, "IoT-driven image recognition for microplastic analysis in water systems using convolutional neural networks," in *2024 2<sup>nd</sup> International Conference on Computer, Communication and Control*, 2024, doi: 10.1109/IC457434.2024.10486490.
- [31] M. Amru *et al.*, "Network intrusion detection system by applying ensemble model for smart home," *International Journal of Electrical and Computer Engineering (IJECE)*, vol. 14, no. 3, pp. 3485–3494, 2024, doi: 10.11591/ijece.v14i3.pp3485-3494.

## BIOGRAPHIES OF AUTHORS







**Palayanoor Seethapathy Ramaprabha**     is Professor and Head of the Department of Electrical and Electronics Engineering has the teaching experience of 22 years with 12 years of research experience. Her research interest is image processing, medical imaging, embedded, internet of things, and renewable energy. She has graduated from SRM easwari engineering college, Madras university Chennai in electrical and electronics engineering (2000). She has obtained her masters in Sathyabama University Chennai (2006) and Ph.D. degree also in Sathyabama University Chennai. She has started her education carrier in the year 2000 as a lecturer. She has accomplished an ground breaking research on the early "Diagnosis of Cervical Cancer using Colposcopic Images". This astute research has brought her the pride of owning doctorate in engineering and biotechnology. She has jubilantly participated in numerous national and international conferences conducted by reputed organizations. She has published several papers in international (18) and national (14) and also presented a paper in international conference and national conferences (20). She is the member of IEEE, life member of ISTE, IETE and IEI. She has received outstanding women and young women scientist awards. She can be contacted at email: ramaprabatamilselvan@gmail.com.








**Bellam Ravindra Babu**     obtained B.Tech. from Siddaganga Institute of Technology (SIT), Bangalore, M.Tech. and Ph.D. from the Jawaharlal Nehru Technological University, Hyderabad, India. Worked in software industry for SIEMENS, Computer Associates, YAHOO! And SAP Labs in various roles for 15 years. Currently he has been working as an associate professor in the Department of Computer Science and Engineering Department, Adama Science and Technology University (ASTU), Adama, Ethiopia. He has totally 23 years of experience in the software industry and as an academician. Published various articles in reputed journals and various abstracts were presented at international conferences. His areas of interest are machine learning, optimization techniques, SOA, virtualisation, cloud computing, distributed systems, software design and architecture and computer networks. He can be contacted at email: Ravindra.babu@astu.edu.et.







**Nallathampi Rajamani Rejin Paul**     is an associate professor in the Department of CSE, R.M.K College of Engineering and Technology, Chennai. Completed UG–BE computer science and engineering from Anna University, PG–ME–computer science and engineering from Anna University. Completed Ph.D. in the Faculty of Information and Communication with specialization in cloud data security Anna University in November 2022. He has published several research publications in refereed international journals with high impact factor and international conferences as well. He is the life member of ISTE and a member of IET. He can be contacted at email: nrrejinpaul@gmail.com.







**Varadan Sharmila**     is an assistant professor in the Department of CSE, R.M.D Engineering College, Chennai. Completed UG–BE computer science and engineering from Anna University, PG–ME–computer science and engineering from Anna University. Pursuing Ph.D. in the Faculty of Information and Communication with specialization in medical image processing, Anna University. She has published several research publications in refereed international journals and international conferences as well. She is the life member of ISTE and a member of IET. She can be contacted at email: sharmilavaradhan@gmail.com.







**Venkatachalam Ramesh Babu**     currently working as a Dean of the University Journals and Professor of CSE at Dr.M.G.R. Educational and Research Institute. He has got 27 years of experience in teaching and 4 years from industry. He did M.E. in computer science and engineering and a further Ph.D in the same discipline. His broad field of research was image processing. His area of interests includes internet of things (IoT), machine learning and big data. He has published research papers in both international and national journals of repute. Besides his academic stint, he has won many awards and accolades. He received distinguished technology author award by national trailblazers triumph award in the year 2023. He has published patent and also published a book on machine learning. He also serves as the member of the board of studies. He is the member of technical societies like ISTE, CSTA, IAAC, IAENG, ICORSA. He has organized workshops and conferences at both national and international level. He has served as a session chair in conferences. He can be contacted at email: rameshbabu.cse@drmgrdu.ac.in.



**Raman Ramya**     is an assistant professor in Department of Electronics and Communication Engineering at Chennai Institute of Technology, Kundrathur Chennai from January 2024. She served as assistant professor Department of ECE at Gnanamani College of Technology from 2010 to 2023 and other engineering colleges. She has more than 18 years of teaching experience. She is doing her Ph.D. at Anna University, Chennai and her postgraduate studies (2008-2011) at Mahendra Engineering College, Mallasamuthram and undergraduate (1996-2000) studies at Periyar Maniyammai College of Engineering and Technology for Women, Thanjavur. Her research interests lie in the area of wireless communication, deep learning. Ramya has served on roughly 10+ conference and workshop and faculty development programs. Ramya is the proud and obsessed mother of two children, born 2001 and 2004. She enjoyed cooking, listening music and reading. She can be contacted at email: rramya@citchennai.net.



**Subbiah Murugan**     is an adjunct professor, Saveetha School of Engineering, Saveetha Institute of Medical and Technical Sciences, Chennai, Tamil Nadu, India. He published his research articles in many international and national conferences and journals. His research areas include network security and machine learning. He can be contacted at smuresjur@gmail.com.